Genmab Reaches Fifth Milestone in Ofatumumab Collaboration

COPENHAGEN, August 21 Genmab A/S (OMX: GEN)announced today it has reached the fifth milestone for ofatumumab(HuMax-CD20(R)) under the terms of its collaboration with GlaxoSmithKline(GSK). A milestone payment of approximately DKK 232.7 million (approximatelyUSD 48.5 million) was triggered by the achievement of positive results in thePhase III study of ofatumumab in refractory chronic lymphocytic leukemia(CLL). Genmab has received an approximate total of DKK 552 million(approximately USD 110 million) in milestone payments under the collaborationso far.

"While achievement of this milestone represents an important potentialturning point for Genmab," said Lisa N. Drakeman, Ph.D., Chief ExecutiveOfficer of Genmab, "it is even more important for CLL patients who arewaiting for new treatments to combat their difficult to treat disease."

Ofatumumab is an investigational new generation fully human monoclonalantibody that targets a distinct, membrane proximal, small loop epitope(specific antibody binding site) of the CD20 molecule on B cells. Ofatumumabis being developed to treat CLL, follicular non-Hodgkin's lymphoma, diffuselarge B-cell lymphoma, rheumatoid arthritis and relapsing remitting MultipleSclerosis under a co-development and commercialization agreement betweenGenmab and GlaxoSmithKline. It is not yet approved in any country.

About Genmab A/S

Genmab is a leading international biotechnology company focused ondeveloping fully human antibody therapeutics for unmet medical needs. Usingcutting-edge antibody technology, Genmab's world class discovery, developmentand manufacturing teams have created and developed an extensive pipeline ofproducts for potential treatment of a variety of diseases including cancerand autoimmune disorders. As Genmab advances towards a commercial future, weremain committed to our primary goal of improving the lives of patients whoare in urgent need of new treatment options. For more information on Genmab'sproducts and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words"believe", "expect", "anticipate", "intend" and "plan" and similarexpressions identify forward looking statements. Actual results orperformance may differ materially from any future results or performanceexpressed or implied by such statements. The important factors that couldcause our actual results or performance to differ materially include, amongothers, risks associated with product discovery and development,uncertainties related to the outcome and conduct of clinical trials includingunforeseen safety issues, uncertainties related to product manufacturing, thelack of market acceptance of our products, our inability to manage growth,the competitive environment in relation to our business area and markets, ourinability to attract and retain suitably qualified personnel, theunenforceability or lack of protection of our patents and proprietary rights,our relationships with affiliated entities, changes and developments intechnology which may render our products obsolete, and other factors. For afurther discussion of these risks, please refer to the section "RiskManagement" in Genmab's Annual Report, which is available onhttp://www.genmab.com. Genmab does not undertake any obligation to update orrevise forward looking statements in this press release nor to confirm suchstatements in relation to actual results, unless required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM);HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of GenmabA/S.

SOURCE Genmab A/S